Study title: Gambertoglio JG, Lilleby K, Meyers JD, Reusser P. 1992.Phase i-ii trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. Journal of Infectious Diseases 1992;166(3):473-9 1992;(3):473-479.Gambertoglio JG, Lilleby K, Meyers JD, Reusser P. 1992.Phase i-ii trial of foscarnet for prevention of cytomegalovirus infection in autologous and allogeneic marrow transplant recipients. Journal of Infectious Diseases 1992;166(3):473-9 1992;(3):473-479.
Type of medicine: Medicines containing chemical active substances | |||||
Therapeutic area: Virus Diseases [C02] | |||||
Brands: Please see report, Please see report | |||||
MAH holders: Please see report | |||||
Assessment: | |||||
Active substance: Foscarnet | |||||
ATC code: | |||||
Document link: Reusser et al 1992.pdf | |||||
Document date: | |||||
Study number: | |||||
EudraCT number: | |||||
Scope of study: Clinical | |||||
Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
- | - | - | - | Y |